INM
InMed
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
ample liquidity
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About INM
Inmed Pharmaceuticals Inc.
A leader in the research, development and manufacturing of rare cannabinoids
1445, 885 West Georgia St., Vancouver, B.C., Canada V6C 3E8
--
InMed Pharmaceuticals Inc., was incorporated in British Columbia on May 19, 1981 under the British Columbia Business Companies Act. The company is a clinical-stage pharmaceutical company that develops prescription drugs for diseases with unmet medical needs and develops patented manufacturing technologies. The company is developing an integrated manufacturing method based on biosynthesis, called IntegraSynTM, for the synthesis of pharmaceutical-grade cannabinoids as well as a variety of product candidates. The company is committed to providing new therapeutic alternatives to patients who may benefit from cannabinoid-based drugs.
Company Financials
EPS
INM has released its 2025 Q1 earnings. EPS was reported at -2.71, versus the expected 0.00, missing expectations. The chart below visualizes how INM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INM has released its 2025 Q2 earnings report, with revenue of 1.11M, reflecting a YoY change of -10.36%, and net profit of -2.58M, showing a YoY change of -74.20%. The Sankey diagram below clearly presents INM’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
